Bavarian Nordic — December 2020
-
Pensionisten m.fl. - det er jo altid godt at følge sin strategi/sine principper, og det mener jeg altid man skal gøre!
-
Det sagt, så mener jeg faktisk, at studiets data reelt set er en fordel for Zealand i og med, at det snarere er studiedesignet og de følgelige upræcise målinger ved den anvendte metode til blodsukkermåling, der afstedkommer udfaldet af forsøget.
-
Data, når blodsukkerniveauet kontinuerligt er, efter min opfattelse, ganske stærke, og det er det jeg umiddelbart hæfter mig mest ved. Vh. og Glædelig Jul til jer alle...
-
"måles" kontinuerligt
-
Tak for mange gode vinker og synspunkter iZP
-
Danske nedjusterer den fra 310 til 305 - fortsat Buy
-
Danke Bank: "We believe the 9% share price decrease on the dasiglucagon CHI Phase 3 trial failure is an overreaction as (1) niche indication worth only DKK13 per share, (2) no negative spill over as we see dasiglucagon as well validated with established proof-of-concept and (3) trial-design failure rather than a drug-related failure. We keep our Buy but adjust our 12-month target price from DKK310 to DKK305."
-
Som I går virker køberne til at komme ind i Z
P på 208-212 - -
GS sænker target fra 285 til 253 i ZP
-
Fortsat Buy
-
smukt - den nævnte bund holdt 222
.4 op3 %
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind